Allogene Therapeutics/$ALLO
1D1W1MYTD1Y5YMAX
Capital at risk
About Allogene Therapeutics
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
- Ticker
- $ALLO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 151
- Headquarters
- South San Francisco, United States
- Website
- allogene.com
ALLO Metrics
BasicAdvanced
$643M
-
-$0.65
0.47
-
Price and volume
Market cap
$643M
Beta
0.47
52-week high
$4.46
52-week low
$1.04
Average daily volume
5.6M
Financial strength
Current ratio
10.716
Quick ratio
10.553
Long term debt to equity
16.13
Total debt to equity
18.114
Interest coverage (TTM)
-138.71%
Profitability
EBITDA (TTM)
-168.649
Gross margin (TTM)
-2,540.52%
Net profit margin (TTM)
-3,566.68%
Operating margin (TTM)
-3,886.14%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-22.08%
Return on equity (TTM)
-42.39%
Valuation
Price to revenue (TTM)
102.013
Price to book
1.47
Price to tangible book (TTM)
1.47
Price to free cash flow (TTM)
-4.613
Free cash flow yield (TTM)
-21.68%
Free cash flow per share (TTM)
-0.403
Growth
Earnings per share change (TTM)
-41.36%
3-year revenue growth (CAGR)
323.70%
3-year earnings per share growth (CAGR)
-36.34%
What the Analysts think about ALLO
Analyst ratings (Buy, Hold, Sell) for Allogene Therapeutics stock.
Analyst projections of the future price of Allogene Therapeutics stock.
Bulls say / Bears say
Strong interim futility analysis of the pivotal Phase 2 ALPHA3 trial showed cemacabtagene ansegedleucel achieved 58.3% MRD clearance vs. 16.7% in observation, supporting its efficacy potential in first-line LBCL consolidation (GlobeNewswire).
FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to cema-cel for first-line consolidation in high-risk LBCL, expediting regulatory review and underscoring its potential to meet a significant unmet need (GlobeNewswire).
Robust balance sheet with $423.6 million in cash and equivalents as of June 30, 2026, and a projected cash runway into 2029, provides ample funding to advance multiple clinical programs (GlobeNewswire).
Pivotal ALPHA3 trial enrollment is not expected to complete until year-end 2027, with the next pivotal event-free survival readout only anticipated mid-2027, prolonging binary outcome risk and delaying commercialization (GlobeNewswire).
The Phase 1 RESOLUTION trial of ALLO-329 in autoimmune diseases remains early-stage, with proof-of-concept data not due until Q4 2026, leaving the autoimmune therapeutic arm unvalidated for an extended period (GlobeNewswire).
High cash burn continues, with Q2 2026 R&D expenses of $30.7 million, G&A expenses of $20.8 million, and a net loss of $42.7 million, necessitating sustained financing efforts that could dilute equity despite the extended runway (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 23 Aug 2026.
ALLO Financial Performance
Revenues and expenses
ALLO Earnings Performance
Company profitability
Upcoming events
No upcoming events
ALLO News
AllArticlesVideos
Funds containing ALLO
AllUSDGBPEUR
Fund name | Fund size | $ALLO weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.